InflaRx (NASDAQ:IFRX) Coverage Initiated by Analysts at HC Wainwright

Key Points

• InflaRx (NASDAQ:IFRX) has received a buy rating from HC Wainwright, which has set a target price of $6.00, indicating a potential upside of 275% from its current stock price.
• Other analysts have shown mixed views, with Oppenheimer reducing its target from $6.00 to $3.00, while Raymond James lowered its rating to "outperform" with a $2.00 price target.
• InflaRx is currently well-supported by institutional investors, with 42.39% of its stock owned by hedge funds and institutional investors, highlighting interest in the company's clinical-stage biopharmaceutical developments.

HC Wainwright began coverage on shares of InflaRx (NASDAQ:IFRX - Free Report) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $6.00 target price on the stock. HC Wainwright also issued estimates for InflaRx's Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.71) EPS and FY2028 earnings at ($0.72) EPS.

Several other equities analysts have also recently issued reports on IFRX. Oppenheimer dropped their price target on InflaRx from $6.00 to $3.00 and set an "outperform" rating on the stock in a research report on Thursday, May 29th. Raymond James Financial lowered InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 target price on the stock. in a research note on Thursday, May 29th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $6.20.

InflaRx Stock Performance

NASDAQ IFRX traded up $0.08 during trading on Tuesday, reaching $1.65. 764,609 shares of the company's stock were exchanged, compared to its average volume of 764,250. InflaRx has a 1 year low of $0.71 and a 1 year high of $2.82. The stock has a market cap of $110.77 million, a P/E ratio of -2.06 and a beta of 1.43. The company has a 50 day moving average price of $0.96 and a two-hundred day moving average price of $1.13.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share for the quarter, meeting the consensus estimate of ($0.24). The firm had revenue of $0.05 million during the quarter, compared to analysts' expectations of $0.02 million. Research analysts forecast that InflaRx will post -1.04 EPS for the current fiscal year.

Hedge Funds Weigh In On InflaRx

A number of large investors have recently bought and sold shares of the business. Woodline Partners LP bought a new stake in shares of InflaRx during the first quarter valued at approximately $766,000. Northern Trust Corp increased its stake in shares of InflaRx by 1,933.1% during the fourth quarter. Northern Trust Corp now owns 666,845 shares of the company's stock valued at $1,647,000 after acquiring an additional 634,045 shares during the period. 683 Capital Management LLC increased its stake in shares of InflaRx by 26.8% during the first quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company's stock valued at $2,678,000 after acquiring an additional 555,000 shares during the period. DAFNA Capital Management LLC acquired a new position in shares of InflaRx during the first quarter valued at approximately $459,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of InflaRx during the second quarter valued at approximately $262,000. Institutional investors own 42.39% of the company's stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.